Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Reynes

Showing results (161-170 of 200) with videos related to

Pageof 20
Sort By:
Open Research Europe|March 23, 2026
Genome wide association study of vaginal microbiota genetic diversity in French womenSamuel Alizon, Claire Bernat, Vanina Boué, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
Open Forum Infectious Diseases|December 29, 2023
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 StudyMireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, et al.
The Journal of Antimicrobial Chemotherapy|April 8, 2020
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial)Cathia Soulie, Lambert Assoumou, Basma Abdi, et al.
AIDS (London, England)|November 15, 2017
HIV is associated with airway obstruction: a matched controlled studyAlain Makinson, Maurice Hayot, Sabrina Eymard-Duvernay, et al.
Infectious Diseases (London, England)|November 28, 2024
Incidence and duration of human papillomavirus infections in young women: insights from a bimonthly follow-up cohortThomas Bénéteau, Soraya Groc, Carmen Lía Murall, et al.
Plos One|January 4, 2013
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studySophie Perrin, Jonathan Cremer, Olivia Faucher, et al.
HIV Clinical Trials|June 27, 2006
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle, Schlomo Staszweski, Bonaventura Clotet, et al.
Plos One|July 26, 2012
HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" studySophie Perrin, Jonathan Cremer, Patrice Roll, et al.
The Lancet. HIV|October 3, 2020
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in CameroonAlexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, et al.
Pageof 20

Showing results (161-170 of 200) with videos related to

Sort By:
Pageof 20
Open Research Europe|March 23, 2026
Genome wide association study of vaginal microbiota genetic diversity in French womenSamuel Alizon, Claire Bernat, Vanina Boué, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
Open Forum Infectious Diseases|December 29, 2023
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 StudyMireille Mpoudi-Etame, Tamara Tovar Sanchez, Marwân-Al-Qays Bousmah, et al.
The Journal of Antimicrobial Chemotherapy|April 8, 2020
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial)Cathia Soulie, Lambert Assoumou, Basma Abdi, et al.
AIDS (London, England)|November 15, 2017
HIV is associated with airway obstruction: a matched controlled studyAlain Makinson, Maurice Hayot, Sabrina Eymard-Duvernay, et al.
Infectious Diseases (London, England)|November 28, 2024
Incidence and duration of human papillomavirus infections in young women: insights from a bimonthly follow-up cohortThomas Bénéteau, Soraya Groc, Carmen Lía Murall, et al.
Plos One|January 4, 2013
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studySophie Perrin, Jonathan Cremer, Olivia Faucher, et al.
HIV Clinical Trials|June 27, 2006
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle, Schlomo Staszweski, Bonaventura Clotet, et al.
Plos One|July 26, 2012
HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" studySophie Perrin, Jonathan Cremer, Patrice Roll, et al.
The Lancet. HIV|October 3, 2020
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in CameroonAlexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, et al.
Pageof 20